Thomas P. Frye, DO, Author at Grand Rounds in Urology

Thomas P. Frye, DO

University of Rochester Medical Center

Rochester, New York

Thomas P. Frye, DO, is a Urologic Oncologist serving as Associate Professor of Urology and Vice Chair of Clinical Affairs for the Department of Urology at the University of Rochester Medical Center in Rochester, New York. Dr. Frye specializes in both minimally invasive urologic oncology (robotic surgery for prostate and kidney cancers), and advanced open pelvic and retroperitoneal cancer surgery. He has a special interest and expertise in the management of localized prostate cancer with focal therapy.

Dr. Frye was the valedictorian of his class, where he graduated with a Doctor of Osteopathy degree from Midwestern University, Chicago College of Osteopathic Medicine in Downers Grove, Illinois. He went on to complete his Urology Residency at Southern Illinois University in Springfield, Illinois. Dr. Frye was chosen for the prestigious fellowship training in Urologic Oncology within the National Cancer Institute at the National Institutes of Health (NIH) in Bethesda, Maryland.

Dr. Frye has the most comprehensive focal therapy program in upstate New York and offers High-Intensity Focused Ultrasound (HIFU), cryotherapy, as well as other ablative technologies. He also participates in national clinical trials evaluating the efficacy of focal therapy for prostate cancer. Dr. Frye’s research projects focus on optimizing the screening, diagnosis, and treatment of men with prostate cancer. During his fellowship, he worked extensively on refining the use of prostate MRIs in men on active surveillance. Dr. Frye's clinical research interests also include advanced imaging for prostate cancer as well as focal therapy for prostate cancer. Dr. Frye is involved in multiple specialty societies including the American Urological Association (AUA), the Society of Urologic Oncology (SUO), the American Society of Clinical Oncology, and the Focal Therapy Society.

Talks by Thomas P. Frye, DO

Case Discussions II-Complications and Recurrences

Abhinav Sidana, MD, MPH, Arvin K. George, MD, Phillip Stricker, MBBS, Taimur Shah, MD, Thomas P. Frye, DO and Alice Yu, MD | Aug 2024

Abhinav Sidana, MD, MPH; Arvin K. George, MD; Phillip Stricker, MBBS; Taimur T. Shah, MD; Alice Yu, MD; and Thomas Frye, DO;

Point Counterpoint: MRI

Thomas P. Frye, DO | Mar 2024

Thomas P. Frye, DO, argues in favor of multiparametric magnetic resonance imaging (mpMRI) over micro ultrasound (MicroUS) for prostate imaging. He begins by stating the underlying goals of prostate imaging in the context of triaging in urologic oncology.

Dr. Frye then turns to the lack of data in support of microUS over mpMRI. He highlights that prostate imaging from MicroUS lacks the scale and reliable interpretability of mpMRI.

Dr. Frye supports the effectiveness of mpMRI in detecting clinically significant prostate cancer with data from the PROMIS and PRECISION studies. He notes that the use of mpMRI in screening can prevent unnecessary biopsies of insignificant cancers.

He concludes by reviewing weaknesses in recent studies of mircoUS. He presents a clinical analysis of microUS which demonstrated the superiority of conventional imaging (TRUS) and mpMRI over microUS.